Targeting Redox and Inflammatory Pathways in Ulcerative Colitis: Mechanistic Insights from Xu Chunfu’s Modified Xianglian Pill

Study Background and Research Question

Ulcerative colitis (UC) is a chronic and recurrent inflammatory disorder of the colon with significant morbidity worldwide. Despite the widespread use of aminosalicylates, corticosteroids, and immunosuppressants, their effectiveness is often constrained by side effects, drug resistance, and cost, prompting a search for alternative and complementary therapies. Traditional Chinese medicine, including Xu Chunfu’s Modified Xianglian Pill (XXLP), has been employed for centuries to treat symptoms resembling UC, but its scientific mechanisms remained poorly understood. The central research question addressed by the reference study is how XXLP exerts its therapeutic effects at the molecular and cellular levels, particularly regarding inflammatory signaling and mitochondrial function in experimental colitis models.

Key Innovation from the Reference Study

The innovation of this work lies in its integrative approach to dissecting the mechanism of XXLP using a combination of proteomics, molecular docking, in vivo and in vitro experiments, and microbiome analysis. The study identifies NADPH oxidase 2 (NOX2) as a direct molecular target of XXLP and uncovers how modulation of the NOX2/ROS/mitochondria/NLRP3 axis underpins its anti-inflammatory effects. By linking changes in redox signaling to both mitochondrial dysfunction and downstream inflammasome activation, the research provides a comprehensive mechanistic framework for XXLP’s efficacy in colitis. Additionally, the demonstration that XXLP alters the gut microbiota composition—specifically increasing beneficial genera such as Muribaculaceae and Ruminococcaceae—provides translational relevance to the interplay between microbiota and host inflammatory responses.

Methods and Experimental Design Insights

The reference study applies a rigorous multi-modal strategy to evaluate XXLP’s impact on colitis and related pathways:

• Chemical Profiling: XXLP’s composition was characterized using ultra-performance liquid chromatography–electrospray tandem mass spectrometry (UPLC-ESI-MS/MS), detecting 373 compounds.
• In Vivo Colitis Model: Dextran sodium sulfate (DSS) was used to induce colitis in mice, allowing for assessment of body weight, disease activity index (DAI), colon shortening, and histopathology.
• Inflammatory Marker Quantification: Cytokines (IL-1β, IL-18, TNF-α, IL-6) were measured by ELISA to quantify inflammatory responses.
• Proteomic and Molecular Docking Analysis: Global proteomics and in silico docking identified and validated NOX2 as a primary target of XXLP.
• Molecular Validation: The effects on NOX2 and related proteins were confirmed in LPS-induced HT-29 colonic epithelial cells using Western blot, qRT-PCR, immunofluorescence, and transmission electron microscopy (TEM).
• Microbiome Assessment: 16S rRNA gene sequencing evaluated the impact of XXLP on gut microbial community structure.

Protocol Parameters

• DSS-induced colitis: 2–5% DSS in drinking water for 5–7 days to establish acute colitis in mice.
• XXLP administration: Oral gavage, dosed daily for the duration of the colitis model.
• Cytokine measurement: ELISA performed on serum and/or colon tissue homogenates at endpoint.
• NOX2 pathway analysis: Western blot, qRT-PCR, and immunofluorescence on colon tissue or HT-29 cells after LPS stimulation and XXLP treatment.
• Microbiota profiling: DNA extraction from fecal samples, amplification of 16S rRNA V3-V4 region, sequencing and bioinformatics analysis.
• Mitochondrial assessment: TEM for ultrastructural analysis of mitochondrial damage in colon epithelium.

Core Findings and Why They Matter

The study provides several pivotal insights:

• XXLP significantly alleviated clinical and histological signs of colitis, including body weight loss and colon shortening (reference study).
• Inflammatory cytokine levels (IL-1β, IL-18, TNF-α, IL-6) were markedly reduced in treated animals, indicating effective suppression of colonic inflammation.
• Proteomics and docking analyses pinpointed NOX2 as a target, with downstream modulation of the ROS/mitochondria/NLRP3 axis confirmed by multiple molecular assays.
• Ultrastructural analysis showed that XXLP mitigated mitochondrial damage in colonic epithelial cells, breaking the positive feedback loop between ROS and mitochondrial dysfunction.
• 16S rRNA sequencing revealed XXLP promotes beneficial gut bacteria (Muribaculaceae, Ruminococcaceae) and suppresses harmful taxa (Enterobacteriaceae), connecting microbiota shifts to molecular inflammation endpoints.
• Statistical correlations linked specific microbial changes to NOX2 pathway activity and colonic inflammation, supporting a host-microbiota-inflammation axis.

These findings collectively establish a mechanistic basis for the anti-colitic effects of XXLP, highlighting the centrality of the NOX2/ROS/mitochondria/NLRP3 signaling axis and microbiota modulation in UC pathogenesis and therapy.

Comparison with Existing Internal Articles

Several independent analyses corroborate the central mechanism identified in the reference study. For example, the internal article "XXLP Modulates NOX2/ROS/Mitochondria/NLRP3 Axis in Ulcerative Colitis" likewise emphasizes the role of XXLP in targeting the redox-inflammatory axis and altering gut microbiota composition. The mechanistic convergence—particularly the suppression of NOX2-driven ROS and downstream mitochondrial and inflammasome dysfunction—enhances the translational robustness of these findings. Another related report ("XXLP Modulates NOX2/ROS/mitochondria/NLRP3 Axis in Colitis Model") reinforces the evidence for integrative anti-inflammatory strategies rooted in both molecular and microbiome modulation.

In contrast, research in other disease domains, such as the internal analysis of peroxidasin-driven glycolytic reprogramming in glioblastoma ("Peroxidasin Drives Glycolytic Reprogramming in Glioblastoma via LDHA"), highlights the broader importance of cellular energy metabolism and redox state in disease progression. These cross-domain links suggest that fine-tuned energy metabolism assays—such as those employing a firefly luciferase ATP assay—are crucial across multiple fields, from inflammatory disease to oncology.

Limitations and Transferability

While the study excels in mechanistic depth and multi-modal validation, some limitations should be recognized. The preclinical mouse model, though widely used, may not fully recapitulate the complexity of human UC, including inter-individual variation in microbiota and immune responses. Furthermore, while the study demonstrates strong molecular and histological effects, clinical translation will require human studies to confirm efficacy, safety, and optimal dosing of XXLP. Additionally, while the correlation between microbiota shifts and NOX2 pathway activity is compelling, causality and the specific microbial metabolites involved remain to be elucidated.

Nevertheless, the combination of in vivo, in vitro, proteomic, and microbiome analyses provides a robust foundation for future translational and clinical research, and the identified NOX2/ROS/mitochondria/NLRP3 axis offers a promising therapeutic target for broader inflammatory and metabolic disorders.

Research Support Resources

For researchers aiming to quantify ATP or assess cellular energy metabolism in colitis or related models, the Luminescent ATP Detection Assay Kit (SKU: K2040) from APExBIO provides a highly sensitive, firefly luciferase-based method for cellular ATP quantification in solutions, cells, or tissue samples. Its streamlined protocol and compatibility with downstream analyses—such as protein assays or Western blotting—facilitate efficient measurement of intracellular ATP levels in experimental workflows investigating mitochondrial function and redox state. This resource can support mechanistic studies on the impact of mitochondrial modulation in inflammatory and metabolic research contexts.